GlassScriptPhysician profile
Jay G Watsky
NPI 1972500247
$38,317.60
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $8,311 · 2021: $5,161 · 2022: $7,784 · 2023: $2,762 · 2024: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,450 · Food and Beverage: $477 · Education: $36.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,450.00 |
| Food and Beverage | $477.43 |
| Education | $36.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $21,021.42 | 2019-2023 | Jardiance |
| Lilly USA, LLC | $10,619.81 | 2019-2023 | Jardiance, Mounjaro, Trulicity |
| Horizon Therapeutics Plc | $1,279.77 | 2019-2022 | |
| Novo Nordisk INC | $955.04 | 2019-2023 | Ozempic, Rybelsus |
| Insulet Corporation | $780.65 | 2019-2022 | |
| Medtronic Minimed, INC. | $421.56 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $339.91 | 2019-2021 | |
| Abbvie INC. | $313.12 | 2019-2023 | Synthroid |
| Abbott Laboratories | $287.26 | 2019-2023 | Freestyle Libre 3 |
| Ipsen Biopharmaceuticals, INC | $267.55 | 2019-2023 | Somatuline Depot |
| Amgen INC. | $246.99 | 2019-2023 | Evenity, Prolia |
| Dexcom, INC. | $239.84 | 2019-2024 | Dexcom G6 Transmitter |
| Medtronic, INC. | $221.07 | 2021 | |
| Janssen Pharmaceuticals, INC | $212.34 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $176.16 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $127.34 | 2019-2022 | |
| Tandem Diabetes Care, INC. | $125.02 | 2021 | |
| Pfizer INC. | $122.84 | 2019-2021 | |
| Radius Health, INC. | $101.46 | 2019 | |
| Beta Bionics, INC. | $80.02 | 2024 | Ilet Bionic Pancreas |
| Opko Pharmaceuticals, LLC | $54.61 | 2022-2023 | Rayaldee |
| Mannkind Corporation | $53.14 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $48.40 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $41.84 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.97 | 2022 | |
| Lifescan, INC. | $30.78 | 2020 | |
| Ibsa Pharma INC. | $25.94 | 2019-2020 | |
| Rhythm Pharmaceuticals, INC. | $24.86 | 2023 | Imcivree |
| Biohaven Pharmaceuticals, INC. | $15.40 | 2021 | |
| Becton, Dickinson and Company | $15.38 | 2022 | |
| Janssen Scientific Affairs, LLC | $14.02 | 2019 | |
| Shire North American Group INC | $11.95 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Watsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.